Approval · Notice of Compliance 1572 · 2003
XALATAN: Notice of Compliance 1572
Issued September 5, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1572
- Date
- September 5, 2003
- Company
- Pharmacia Canada Inc.Baie D'Urfe, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication - reduction of intraocular pressure in patients with chronic angle-closure glaucoma who underwent peripheral iridotomy or laser iridoplasty
- Therapeutic class
- Prostaglandin F2alpha analogue
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XALATAN | Not yet assigned | — |
Medicinal ingredients
- LATANOPROST 50 MCG per ML